With its Nasdaq listing hanging in the balance, vTv Therapeutics says its board has still not set a date or ratio for a reverse stock split. The High Point biopharmaceutical company's stock price has been consistently under Nasdaq's $1 minimum and it hopes that a reverse stock split will help it avoid being delisted. Find out more about its rocky financials and how it could affect the development of its Type 1 diabetes treatment.
